Abstract
Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.
| Original language | English |
|---|---|
| Pages (from-to) | 254-260 |
| Number of pages | 7 |
| Journal | Ocular Immunology and Inflammation |
| Volume | 18 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 1 2010 |
Fingerprint
Keywords
- Conjunctival intraepithelial neoplasia
- Ocular surface squamous neoplasia
- Pegylated interferon
ASJC Scopus subject areas
- Ophthalmology
- Immunology and Allergy
Cite this
Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia : A pilot study. / Karp, Carol; Galor, Anat; Lee, Yunhee; Yoo, Sonia H.
In: Ocular Immunology and Inflammation, Vol. 18, No. 4, 01.08.2010, p. 254-260.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia
T2 - A pilot study
AU - Karp, Carol
AU - Galor, Anat
AU - Lee, Yunhee
AU - Yoo, Sonia H
PY - 2010/8/1
Y1 - 2010/8/1
N2 - Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.
AB - Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.
KW - Conjunctival intraepithelial neoplasia
KW - Ocular surface squamous neoplasia
KW - Pegylated interferon
UR - http://www.scopus.com/inward/record.url?scp=77954869515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954869515&partnerID=8YFLogxK
U2 - 10.3109/09273948.2010.486687
DO - 10.3109/09273948.2010.486687
M3 - Article
C2 - 20662655
AN - SCOPUS:77954869515
VL - 18
SP - 254
EP - 260
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
SN - 0927-3948
IS - 4
ER -